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Background: OX40 ligand (OX40L) co-stimulates and differentiates T cells via ligation of OX40 that is transiently
induced on T cells upon activation, resulting in prolonged T cell survival and enhanced cytokine production by
T cells. This view has led to the targeting of OX40 as a strategy to boost antigen specific T cells in the context of
vaccination. In addition, the ligation of OX40 has also been shown to inhibit infection by CCR5-utilizing (R5) but not
CXCR4-utilizing (X4) human immunodeficiency virus type-1 (HIV-1) via enhancement of production of CCR5-binding
β-chemokines. It was reasoned that human T cell leukemia virus type-I (HTLV-1) immortalized T cell lines that
express high levels of OX40L could serve as an unique source of physiologically functional OX40L. The fact that
HTLV-1+ T cell lines simultaneously also express high levels of OX40 suggested a potential limitation.
Results: Results of our studies showed that HTLV-1+ T cell lines bound exogenous OX40 but not OX40L, indicating that
HTLV-1+ T cell lines express an active form of OX40L but an inactive form of OX40. Anti-OX40 non-blocking monoclonal
antibody (mAb), but not blocking mAb, stained HTLV-1+ T cell lines, suggesting that the OX40 might be saturated with
endogenous OX40L. Functionality of the OX40L was confirmed by the fact that a paraformaldehyde (PFA)-fixed
HTLV-1+ T cell lines inhibited the infection of autologous activated peripheral blood mononuclear cells (PBMCs) with R5
HIV-1 which was reversed by either anti-OX40L blocking mAb or a mixture of neutralizing mAbs against CCR5-binding
β-chemokines.
Conclusions: Altogether, these results demonstrated that autologous T cell lines immortalized by HTLV-1 can be
utilized as a conventional source of physiologically functional OX40L.Background
OX40 ligand (OX40L, CD252) belonging to the tumor ne-
crosis factor (TNF) superfamily is a co-stimulatory mol-
ecule [1,2] that was first described by our laboratory as
gp34 that is constitutively expressed at high levels on the
surface of human T cell leukemia virus type-I (HTLV-1)-
immortalized T cell lines [3,4]. It is now clear that OX40L
can be induced on a wide variety of human hematopoietic* Correspondence: yuetsu@s4.dion.ne.jp
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reproduction in any medium, provided the orcell lineages including antigen presenting cells (APCs)
such as dendritic cells (DCs) [5] and B cells [6], natural
killer (NK) cells [7], mast cells [8], endothelial cells [9] and
T cells [10,11]. OX40 (CD134), a member of the TNF re-
ceptor (TNFR) superfamily that is rapidly induced pre-
dominantly on T cells upon cell activation is the cognate
receptor for OX40L [12-14]. Interaction of OX40 on
T cells with OX40L on APCs generates a variety of bio-
logical changes that include enhanced production of cyto-
kines by T cells, Th2 cell differentiation, prolonged T cell
survival, activation of B cells and DCs, to name a fewal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as a trimeric protein that binds to three copies of mono-
meric OX40 within close proximity [16]. Such close inter-
actions between OX40/OX40L promotes tight cell to cell
adhesion facilitating T cell-DC communication and skin
infiltration of OX40+ leukemic T cells in adult T cell
leukemia (ATL) [17].
It has been proposed that the targeting of OX40 on acti-
vated T cells by OX40L or with the use of anti-OX40 ag-
onistic antibodies may provide a strategy for the selective
expansion of the limited frequencies of antigen specific T
cells that are normally induced during vaccination and
thereby achieve more effective immune responses [18-20].
Another immunological role of OX40L-OX40 interaction
that we have previously documented includes the ability of
OX40L in either soluble or membrane-bound form to ef-
fectively inhibit the infection of activated PBMCs with R5
HIV-1 in vitro [21]. This inhibition was shown to be medi-
ated via the enhanced production of the CCR5-binding
β-chemokines that include RANTES, MIP-1α and MIP-
1β, followed by the down-modulation of cell surface
CCR5 expression. These findings brought into focus the
potential use of OX40L as a therapeutic tool and promp-
ted us to investigate methodologies that would provide a
convenient source for biologically active OX40L. One such
source of OX40L was reasoned to be HTLV-1+ T cell lines
that unlike normal activated T cells or non-T cells have
been shown to express both OX40L and OX40 on the cell
surface at a single cell level due to the action of the
HTLV-1-encoded oncogenic protein Tax [4,22]. Tax, in
addition, also induces the expression of 4-1BB and its cog-
nate ligand both of which belong to the TNF/TNFR family
[23]. Selective induction of these ligand/receptor pairs has
been implicated in the survival of HTLV-1-infected cells.
Studies were therefore carried out in efforts to examine
whether OX40L and OX40 were expressed in a biologic-
ally active form by HTLV-1+ T cell lines. We report herein
for the first time that HTLV-1+ T cell lines express a bio-
logically active form of OX40L while the OX40 molecule
appears biologically inactive or masked. The OX40L
expressed by HTLV-1+ T cell lines was capable of inhibit-
ing R5 HIV-1 infection of activated PBMCs via production
of CCR5-binding β-chemokines. These findings suggest
that autologous HTLV-1-immortalized T cell lines can be
utilized as a readily available convenient source of natural
OX40L in large quantities for various immunological
studies.
Results
HTLV-1-immortalized T cell lines express active OX40L
together with inactive OX40
In order to determine whether OX40L and OX40 co-
expressed on the cell surface of HTLV-1+ T cell lines were
biologically active, we examined their capacities to bindbiotinylated rec-OX40 and rec-OX40L, respectively. The
finding that rec-OX40 and rec-OX40L bound specifically
to the OX40L-transfected CEM cells (CEM/OX40L) and
the OX40-transfected CEM/OX40 cells, respectively,
demonstrated the specificity of the assay being utilized
(Figure 1). Interestingly, although the standard HTLV-1+
T cell line (MT-2) was stained double positive with anti-
OX40L (clone 5A8) and anti-OX40 (clone B-7B5) mAbs,
they bound only rec-OX40 but not rec-OX40L. This find-
ing indicated that while OX40L was expressed in an active
form on MT-2 cells, the OX40 was likely to be
expressed in an inactive form. Similar results were
obtained by the testing of a number of additional
HTLV-1+ T cell lines, including T cell lines spontaneously
established from a HTLV-1-infected patient with adult T
cell leukemia (ILT-H2) and a HTLV-1-associated myelop-
athy (HAM/TSP) patient (ILT-M1), and various in vitro-
HTLV-1-immortalized CD4+ or CD8+ T cell lines from
different healthy donors (such as YT/cM1, RT/cH2 cells)
(Figure 1). Thus, these results suggest that on the cell sur-
face of the HTLV-1+ T cell lines only OX40L, but not
OX40, is capable of binding its respective ligand.
Characterization of OX40 on HTLV-1+ T cells
A series of studies were subsequently conducted in
efforts to identify the potential reason(s) for the failure
of HTLV-1+ T cell lines to bind rec-OX40L. Western
Blot analysis of OX40 expressed by HTLV-1+ T cell line
was first carried out to determine whether the OX40
expressed by these cells was truncated. Cell lysates pre-
pared from surface biotinylated in vitro activated PBMCs
and the OX40 transfected CEM cell line (CEM/OX40)
were analyzed in parallel with the HTLV-1+ T cell line
MT-2 using standard Western Blot techniques. Results
of these studies displayed in Figure 2 showed that there
were no detectable differences in the molecular weight
of the glycosylated authentic OX40 (50 kDa) among
these three samples. The 35 kDa band corresponding to
the non-glycosylated form of OX40 was apparent in
CEM/OX40 cells and activated PBMCs, but it was faint
in MT-2 cells. These data indicated that there was no
detectable deletion or modification in the glycosylated
OX40 molecules expressed by the HTLV-1+ T cell lines.
To further probe for the molecular basis for the inability
of the OX40 expressed by the HTLV-1+ T cell lines to bind
rec-OX40L, we utilized an additional anti-OX40 specific
mAb (W4-54 mAb) along with B-7B5 mAb. While the
clone W4-54 anti-OX40 mAb inhibited the binding of
OX40 and OX40L, the clone B-7B5 failed to show any de-
tectable inhibition (Additional file 1: Figure S1). These two
mAbs are reasoned to react against conformational epi-
topes since they failed to bind any overlapping 15-mer pep-
tides spanning the entire OX40 protein (data not shown).
As shown in Figure 3(A), control mock treated CEM/
Figure 1 HTLV-1+ T cells co-express both OX40L and OX40 but only OX40L is expressed in an active form. The OX40 and OX40L
co-expressing control CEM cells and the HTLV-1+ cells were dually stained with FITC-labeled anti-OX40 (B-7B5) and Cy-5 labeled anti-OX40L (5A8)
(upper row), or singly stained either with biotinylated recombinant OX40L (rec-OX40L) or rec-OX40 followed by PE-streptavidin (middle and lower
rows, respectively). Data shown are representative profiles of 3 independent experiments.
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dual-positive with the B-7B5 mAb and W4-54 mAbs.
These data show that the comparative staining with B-7B5
and W4-54 mAbs can be potentially utilized to distinguish
between non-ligated versus OX40L ligated forms of OX40.
Figure 3(B) shows that although B-7B5 mAb stained
HTLV-1+ T cell lines at high levels, little or no staining was
noted with the use of the W4-54 mAb. In contrast, results
of a WB analysis showed that the W4-54 mAb readily re-
acts to the p50 of the OX40 molecule in lysates of the
HTLV-1+ T cell line, YT/cM1 (Additional file 2: Figure S2).
These results suggest that the OX40L binding site of
OX40 expressed by the HTLV-1+ T cell lines was
altered, most probably due to pre-occupation with
endogenous OX40L. To confirm this possibility, we
explored the presence of OX40-OX40L complexes
expressed by HTLV-1+ T cell lines using our in-house
ELISA. Cell lysates of the ATL-derived HTLV-1+ T cell
line (ILT-H2) were first captured with the use of immobi-
lized anti-OX40L (clone HD-1) or anti-OX40 (clone
B-7B5) mAb, respectively. The levels of captured antigens
were assayed with the use of HRP-labeled anti-OX40 mAb
or anti-OX40L mAb. Although it is reasonable to assume
that the natural interaction between OX40 and OX40L onthe living cell surface may be dissociated by the detergent
treatment, as shown in Figure 4, low but significant levels
of OX40-OX40L complex were still detectable in the cell
lysates.
Functional OX40L expressed by HTLV-1+ T cell lines
To confirm that the OX40L expressed on the HTLV-1+
T cell lines is biologically functional, we performed co-
culture experiments using the experimental in vitro in-
fection of autologous activated PBMCs with HIV-1 as a
read out. PBMCs activated with anti-CD3/anti-CD28
mAbs for 24 hours were washed and infected with either
R5 HIV-1JR-FL or X4 HIV-1NL4-3 at a low m.o.i., and then
co-cultured with paraformaldehyde (PFA)-fixed autolo-
gous HTLV-1+ T cell line in the presence or absence of
anti-OX40L mAb or a mixture of the three CCR5-
binding chemokine-blocking mAbs (anti-RANTES, anti-
MIP-1α and anti-MIP-1β). The reasons why we utilized
autologous PFA-fixed HTLV-1+ T cell lines were to avoid
any allogeneic stimuli and minimize the secretion of any
anti-HIV-1 factors by the HTLV-1+ T cell lines. As
shown in Figure 5, the frequencies of HIV-1 p24+ T cells
in the cultures were reduced by co-culture with not only
autologous HTLV-1+ T cell line but also with the
Figure 2 Western blot analysis of OX40. OX40-expressing CEM
cells (CEM/OX40), in vitro activated PBMCs and MT-2 cells were
cell-surface labeled with biotin, lysed and immunoprecipitated with
anti-OX40 (B-7B5). The precipitates were subjected to 10% PAGE and
blotted onto nitrocellulose sheets. The sheets were then probed
with HRP-labeled anti-HIV-1 p24 (as a control), anti-OX40 (B-7B5) or
streptavidin. Mol. Wt. markers are shown on the right. Data shown
are representative of 3 independent experiments.
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diated by OX40L-OX40 interaction since the addition of
the anti-OX40L blocking mAb (clone 5A8) and/or the
addition of a mixture of the anti-β-chemokine mAbs re-
versed the level of reduction. It is worthy to note that,
similar to data we have previously reported with the use
of recombinant OX40L [21], X4 HIV-1 infection was not
influenced by co-cultivation with PFA-fixed HTLV-1+ T
cell line, suggesting the CCR5-specificity of this antiviral
effect.
Finally, we compared the potential of membrane
bound OX40L of the fixed HTLV-1+ T cell lines with
that of soluble rec-OX40L to inhibit R5 HIV-1 infection
by the quantitation of p24 production in the culture su-
pernatants. As shown in Figure 6, whereas the inhibitory
effect of the rec-OX40L reached a plateau at levels >
1.25 μg/ml, the autologous HTLV-1+ T cell line could in-
hibit more effectively at even an HTLV-1+ T cell to
PBMCs ratio as low as 0.3. The maximum inhibition
reached with rec-OX40 was around 65% of the max-
imum inhibition reached with HTLV-1+ T cell line, with
similar IC50. Altogether, these data demonstrate that in-
deed, the OX40L expressed by HTLV-1+ T cell lines is
biologically active.
Discussion
In the present study, we revealed that the cell surface
expressed OX40L on T cell lines immortalized by HTLV-1is biologically active in concert with the co-expression of
an inactive form of OX40. As far as we know, this is the
first study to report the polarized “OX40L-active/OX40
inactive” expression by HTLV-1+ T cell lines. The expres-
sion of active forms of OX40L is not unique to HTLV-1+
T cell lines, since similar conditions have also been ob-
served in normal T cells when they are activated under
mild DNA damaging conditions or cultured for long-term
in IL-2 containing media with periodic stimulation
[11,24]. However, compared to these normal T cells,
HTLV-1+ T cell lines are immortal and thus can provide
unlimited amounts of OX40L.
The precise mechanism for the inability of OX40 on
HTLV-1+ T cell lines to bind OX40L remains to be clearly
defined. Based on our previous paper showing that func-
tional OX40L can be transferred to OX40 intercellularly
[25], we hypothesize that the cell surface OX40 may be
saturated with endogenously produced OX40L in cis
and/or trans mode. Indeed, the WB analysis showed that
the OX40-OX40L blocking mAb W4-54 that did not stain
living HTLV-1+ T cells reacted to the p50 OX40 molecule
(Additional file 2: Figures S2 and Additional file 3: Figures
S3). In accordance with this assumption, we demonstrated
the presence of OX40-OX40L complexes in lysates of
HTLV-1+ T cell lines by ELISA (Figure 4). It remains un-
clear why there were significant amounts of OX40L-free
OX40 molecules in the lysates from HTLV-1+ T cells as
determined by ELISA. It will be highly likely that the de-
tergent treatment dissociates the OX40 and OX40L com-
plex due to perturbation of cytoplasmic membrane
structure including lipid rafts on which OX40 is supposed
to reside in association with the other TNFR member
such as 4-1BB [26,27]. In addition, our preliminary data
that supports the OX40 saturation hypothesis includes the
finding using the HUT 102 cell line that is another
HTLV-1+ T cell line from which the original OX40 gene
was cloned [13]. This HUT102 cell line stained with
both B-7B5 and W4-54 mAbs, but not with anti-OX40L
(5A8 mAb), and was able to bind recombinant OX40L
but not OX40 (Additional file 3: Figure S3). Although it
is not clear why HUT102 cell line was positive for Tax
antigen but negative for OX40L expression, these data
clearly showed that in the absence of OX40L, functional
OX40 can be expressed on the cell surface. It will be of
interest to examine whether the inactive form of the
OX40 can be converted to an active form after silencing
the expression of OX40L in HTLV-1+ T cell lines. Such
studies are currently in progress.
On the basis of the present and previous results on
OX40L [21], it can be hypothesized that OX40L may
have a therapeutic and prophylactic potential against R5
HIV-1 infection. However, at present, purified biologic-
ally active forms of human OX40L protein in large
quantities is not available. The alternative is to utilize
Figure 3 Blocking (clone W4-54) versus non-blocking (clone B-7B5) mAb against 2 distinct epitopes of OX40 distinguish between
OX40L bound and unbound OX40. (A) OX40-expressing CEM and activated PBMCs were stained with the two mAbs in the absence (mock) or
presence of 1 μg/ml of recombinant OX40L (rec-OX40L). (B) Various HTLV-1+ T cell lines were stained with B-7B5 andW4-54 labeled with FITC and
Cy5, respectively. Data shown are representative of 3 independent experiments.
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binant virus [20], OX40L mRNA-transfected cells [29],
lentivirus-transduced DCs [30], or autologous dying nor-
mal T cells [24]. The superiority of using cell membrane-
bound OX40L as compared with the use of a soluble form
was documented by data observed by the degree of inhib-
ition of R5 HIV-1 as seen in the present study (Figure 6).
These findings are in accord with a previous study that
showed that the membrane-immobilized form of OX40L
is highly active in the stimulation of an OX40-transfected
cell line to produce cytokines [31]. In addition to OX40L,
HTLV-1+ cell lines may exert additional suppressing effect
on R5 HIV-1 infection via Tax protein, since Tax proteins
of HTLV-1 and HTLV-2 have been shown to play a role in
generating antiviral responses against HIV-1 via induction
of CCR5-binding chemokines in vitro [32]. This view is
supported by the finding that co-infection with HTLV in-
terferes with the progression of HIV-1 disease in vivo [33].However, such Tax effects in the present study may be less
potent than OX40L since anti-OX40L mAb significantly
reversed the suppression of R5-HIV-1 induced by co-
culture with autologous HTLV-1+ T cell lines (Figure 5).
Conclusions
The present results demonstrate that HTLV-1+ T cell
line is a unique source of functional human OX40L, and
suggest that autologous HTLV-1-immortalized T cell
lines can be utilized as a conventional source of natural




The medium used throughout the studies consisted of
RPMI 1640 medium (Sigma-Aldrich. Inc. St. Louis, MO),
supplemented with 10% fetal calf serum (FCS), 100 U/ml
Figure 4 Presence of OX40-OX40L complexes in HTLV-1+ T cell
lysates. The ILT-H2 cell line derived from an ATL patient were lysed
and the lysates incubated in microtiter wells that had been previously
coated with either anti-CD25, OX40 or OX40L mAb for 1 hour.
Anti-CD25 mAb was used as a non-specific negative control. After
washing, the levels of OX40 or OX40L bound to the plates were assayed
using either HRP-labeled anti-OX40 or anti-OX40L mAb. Data shown are
representative of 3 independent experiments.
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RPMI medium). Anti-human CD3 mAb (clone OKT-3)
and agonistic anti-CD28 mAb were purchased from the
American Type Culture Collection (Rockville, MD) and
Biolegend (San Diego, CA), respectively. Neutralizing
mAbs against human RANTES, MIP-1α, and MIP-1β
were purchased from R&D systems (Minneapolis, MN).
The mouse mAbs produced in our laboratory included
anti-OX40L (blocking clone 5A8 [34] and clone HD1, un-
published), anti-human OX40 (non-blocking clone B-7B5
and clone 17D8 [35]), anti-HIV-1 p24 (clones NP-24 andFigure 5 PFA-inactivated HTLV-1+ T cells inhibit infection of activated
and β-chemokines. In vitro activated PBMCs were infected with either R5 HIV
absence of recombinant OX40L, PFA-inactivated autologous HTLV-1+ T cells, an
mAbs. After 4 days, the cells were examined for intracellular HIV-1 p24 by FCM.2C2 [21]) and anti-CD25 (clone H-8) [36]. The rat mAbs
included anti-human OX40 (blocking clone W4-54) and
anti-HCV (clone Mo-8) [25,37]). Some clones were la-
beled with HRP using a kit (Dojin, Kumamoto, Japan) and
used as the detector mAb in ELISA. These in-house mAbs
were isolated from ascites fluid prepared in Balb/c or
CB.17-SCID mice. The IgGs were purified utilizing a
standard gel filtration method. Some of them were labeled
with FITC, HiLyte Fluor 647 or Cy5 using commercial
labeling kits (Dojin, GE Healthcare) according to the
manufacturer’s instructions. Biotinylated recombinant-
soluble human OX40 (sOX40 in a form of murine
IgG2a-Fc fusion protein) and OX40L (sOX40L in a form
of murine CD8-fusion protein) were purchased from
Ancell (Bayport, MN) and used with PE-streptavidin
(BioLegend) for staining. Unlabeled glycosylated recom-
binant human OX40L that consists of OX40L with a hu-
man CD33 signal peptide produced in NS1 cells was
purchased from R&D systems. Human recombinant IL-2
was obtained as a courtesy from the NIH-AIDS Reagent
and Repository program (Bethesda, MD).
Cell lines
The HTLV-1-producing T cell lines used included the
MT-2, HUT102 and the IL-2 dependent T cell lines
ILT-M1 and ILT-H2 that had been generated from a
HTLV-1-associated myelopathy (HAM) and an adult T
cell leukemia (ATL) patient, respectively. Additional cell
lines utilized included the CEM cell lines transfected
with either human OX40L or OX40 (CEM/OX40L and
CEM/OX40) [38]. T cells isolated from normal human
donors were immortalized by HTLV-1 as follows.autologous PBMCs with R5 HIV-1, but not X4 HIV-1, via OX40L
-1 (JR-FL strain) or X4 HIV-1 (NL4-3 strain) and cultured in the presence or
ti-OX40L blocking mAb (5A8) or a mixture of anti-β-chemokine neutralizing
Data shown are representative of 3 independent experiments.
Figure 6 HTLV-1+ T cells are more potent in the inhibition of R5
HIV-1 infection than recombinant soluble OX40L. R5 HIV-1-infected
PBMCs prepared as in Figure 5 were cultured in the presence or
absence of a graded concentration of recombinant soluble OX40L or
PFA-fixed autologous HTLV-1+ T cells. After 4 days, the levels of p24
produced in the culture supernatants were quantitated by ELISA. Data
shown are representative of 2 independent experiments.
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gradient centrifugation of heparinized whole blood on
HistoPAQUE-1077 (Sigma-Aldrich), suspended at 2 × 106
cells/ml in RPMI medium, dispensed into individual
wells of 24-well plates (BD) (1 ml/well) pre-coated with
5 μg/ml OKT3 for 1 hour and cultured in the presence
of soluble 0.1 μg/ml anti-CD28 mAb. After 24 hours at
37°C in a 5% CO2 humidified atmosphere, the activated
PBMCs were harvested and washed once. These activated
PBMCs (1 × 106 cells/ml) were mixed with an equal num-
ber of ILT-M1 cells that were pretreated with 50 μg/ml
MMC for 30 min at 37°C and cultured in RPMI media
supplemented with 20 U/ml IL-2 (culture media). The cul-
tures were performed in 24-well plates (BD) (2 ml/well)
and the culture media was replenished every 3–4 days.
After 1 ~ 2 months when HTLV-1 Tax+ T cells appeared
and started to grow continuously, they were split every 3
to 5 days using the culture medium.
Flow Cytometry (FCM)
FCM analysis of live cells was carried out as described
previously. Briefly, cells to be analyzed were Fc-blocked
with 2 mg/ml normal human pooled IgG on ice for
15 min. Aliquots of these cells were then subjected to
staining using pre-determined optimum concentrations
of fluorescent dye-conjugated mAbs for 30 min on ice.
The cells were then washed using FACS buffer (PBS
containing 2% FCS and 0.1% sodium azide), fixed in 1%paraformaldehyde (PFA) containing FACS buffer and ana-
lyzed using a FACS Calibur, and the data obtained were
analyzed using the Cell Quest software (BD). In order to
determine whether cell surface OX40 or OX40L is func-
tional, aliquots of Fc-blocked cells were incubated with
either biotinylated recombinant-OX40L (rec-OX40L) or
rec-OX40 at a concentration of 2.5 μg/ml for 30 minutes
on ice, followed by staining with PE-labeled streptavidin
(Beckman Coulter) for 30 minutes on ice and then ana-
lyzed by FCM. For detection of HIV-1 infected cells,
PBMCs were fixed with PBS containing 4% PFA followed
by washing twice in FACS buffer containing 0.5% saponin.
These cells were Fc-blocked with 2 mg/ml normal hu-
man pooled IgG on ice for 15 min, and aliquots of these
cells were stained with FITC- or Cy5-conjugated anti-
HIV-1 p24 mAb (clone 2C2) for 30 min on ice. The cells
were then washed using FACS buffer and absolute cell
counts of p24+ cells were performed by FCM using a
cell counting kit (BD) according to the manufacturer’s
protocol. For staining of Tax antigen, cells were fixed
with PBS containing 4% PFA followed by washing in
FACS buffer containing 0.5% saponin. Aliquots of these
cells were stained with Cy5-conjugated mouse anti-Tax
mAb (Lt-4) [39] for 30 min on ice.ELISA and Western blot
For the quantitation of OX40L and OX40 by ELISA,
anti-OX40L capture mAb (clone HD1)/ HRP-labeled de-
tector mAb (clone 8F4) and anti-OX40 (clone B-7B5)/
HRP-labeled detector mAb (clone 17D8), respectively,
were used together with recombinant standard proteins
purchased from R&D systems. Immunoprecipitation
followed by Western blot analysis of OX40 was per-
formed as reported previously [40].HIV-1 preparation and infection
HIV-1JR-FL and HIV-1NL4-3 viral stocks were produced as
described previously [21]. In vitro activated PBMCs were
prepared as described above, washed once and infected
with either R5 HIV-1JR-FL or X4 HIV-1NL4-3 at a multipli-
city of infection (m.o.i.) of 0.005 for 2 hours. After washing
3 times, PBMCs were re-suspended at 1 × 106 cells/ml in
20 U/ml IL-2-containing RPMI medium, dispensed into
individual wells of 48-well plates (BD) (0.5 ml/well) and
cultured in the presence or absence of 1 μg/ml of rec-
OX40L or graded numbers of autologous HTLV-1+ T cells
(HTLV-1+ T cells : PBMCs ratio of 10 to 0.15) that had
been previously inactivated with 4% paraformaldehyde
(PFA). Production of HIV-1 was determined by either the
measurement of HIV-1 core p24 levels produced in the
culture supernatants using our in-house formulated and
standardized kits or FCM using Cy5 labeled anti-HIV-1
p24 mAb [21].
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Data were tested for significance using the Student’s t
test by using Prism software (GraphPad Software).Additional files
Additional file 1: Figure S1. Characterization of two anti-human OX40
mAbs. In the presence of B-7B5, W4-54 or isotype control mAbs, the
OX40 and OX40L co-expressing control CEM cells were singly stained
either with biotinylated recombinant OX40L (rec-OX40L) or rec-OX40,
respectively, followed by PE-streptavidin. Data shown are representative
profiles of 3 independent experiments.
Additional file 2: Figure S2. Detection of OX40 expressed by HTLV-1+
T cell line (YT/cM1) by Western Blot with B-7B5 and W4-54 mAbs. Cell
lysates of HTLV-1+ T cell line, YT/cM1, were subjected to 10% PAGE and
blotted onto nitrocellulose sheets. The sheets were then probed with
anti-OX40 mAbs (B-7B5 or W4-54) or isotype controls followed by goat
anti-mouse IgG or anti-rat IgG. Mol. Wt. markers are shown on the right.
Data shown are representative of 2 independent experiments.
Additional file 3: Figure S3. Phenotype of HUT-102 cell line. Phenotype
of HUT-102 cells were examined by FCM using anti-OX40 mAbs (FITC-labeled
B-7B5 and Cy5-labeled W4-54), anti-OX40L (Cy5-labeled 5A8), biotinylated
OX40 (rec-OX40) and OX40L (rec-OX40L) followed by PE-streptavidin.
Intracellular Tax antigen was stained by mouse anti-Tax Lt-4 mAb.
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